Just Published:

Landmark Melanoma Study JAMA Surgery

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

First and only prospective blinded data confirms…

…the Merlin CP-GEP (Clinico pathological-Gene Expression Profiling) Test accurately stratifies melanoma patients by sentinel node metastasis risk, showing a greater than three-fold difference between High-Risk and Low-Risk groups.

Significant findings among patient sub-groups:

Merlin_001 identified a substantial number of high-risk melanoma patients within the T1 group, with an SLNB positivity rate of 16.1% (1/6) – nearly double the 8.5% risk predicted by clinicopathologic factors alone.
In head and neck melanomas, the Merlin CP-GEP test identified High-Risk cases with a 26.7% SLN rate and Low-Risk cases with a 4.9% SLN (five-fold risk increase in the High-Risk vs. the Low-Risk groups).
In the subgroup of patients <40 years of age, the Low-Risk cases showed 0.0% SLN metastases compared with 21.8% in High-Risk cases.
In patients aged 65 and older, where comorbidities can be more prevalent, the test identified 57.9% as High-Risk.

Click Here to Access the Full Publication

Click Here to Access the SkylineDx Press Release

Contact

Please contact us with any questions you may have.

Phone: 858-886-7907
Fax: 858-258-5188

clientservices@skylinedx.com